|Bid||15.11 x 1200|
|Ask||15.16 x 1200|
|Day's Range||14.75 - 15.33|
|52 Week Range||0.76 - 17.40|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 02, 2021 - Aug. 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.00|
Following a serious pop for its stock on Wednesday, given very encouraging news about one of its pipeline drugs, Curis (NASDAQ: CRIS) saw its shares dive by almost 20% the following day. Curis released its first-quarter figures after market close on that otherwise glorious Wednesday.
Thank you and welcome to Curis first-quarter 2021 earnings call. Joining me on today's call are Jim Dentzer, president and chief executive officer; and Bob Martell, head of R&D. We will also be available for a question-and-answer period at the end of the call.
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2021.